Diagnostic utility of the B-cell lineage markers CD20, CD79a, PAX5, and CD19 in paraffin-embedded tissues from lymphoid neoplasms

Applied Immunohistochemistry and Molecular Morphology

Volumn 17, Issue 2, 2009, Pages 96-101

  Adams, Heiner ^a   Liebisch, Peter ^b   Schmid, Patrik ^a   Dirnhofer, Stephan ^a   Tzankov, Alexandar ^a,c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

CD19; CD20; CD79a; Leukemia; Lymphoma; PAX5; Tissue microarrays

Indexed keywords

BIOLOGICAL MARKER; CD19 ANTIGEN; CD20 ANTIGEN; CD79A ANTIGEN; PARAFFIN; TRANSCRIPTION FACTOR PAX5;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; B LYMPHOCYTE; CONTROLLED STUDY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REED STERNBERG CELL; SENSITIVITY AND SPECIFICITY; T CELL LYMPHOMA; TISSUE MICROARRAY;

ANTIGENS, CD19; ANTIGENS, CD20; ANTIGENS, CD79; B-CELL-SPECIFIC ACTIVATOR PROTEIN; HUMANS; LEUKEMIA, B-CELL; LYMPHOMA, B-CELL; MICROARRAY ANALYSIS; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 67849112968     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181845ef4     Document Type: Article

References (35)

1. Berthold D, Ghielmini M. Treatment of malignant lymphoma. Swiss Med Wkly. 2004;134:472-480.
2. Jaffe ES, Harris NL, Stein H, et al. Pathology & Genetics-Tumours of Haematopietic and Lymphoid Tissues. Lyon: IARC Press; 2001.
3. Krenacs L, Himmelmann AW, Quintanilla-Martinez L, et al. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas. Blood. 1998;92:1308-1316. (Pubitemid 28369044)
4. Schebesta M, Heavey B, Busslinger M. Transcriptional control of B-cell development. Curr Opin Immunol. 2002;14:216-223.
5. Yao X, Teruya-Feldstein J, Raffeld M, et al. Peripheral T-cell lymphoma with aberrant expression of CD79a and CD20: a diagnostic pitfall. Mod Pathol. 2001;14:105-110. (Pubitemid 32173393)
6. Tzankov A, Went P, Munst S, et al. Rare expression of BSAP (PAX-5) in mature T-cell lymphomas. Mod Pathol. 2007;20: 632-637. (Pubitemid 46795145)
7. Ginaldi L, De Martinis M, Matutes E, et al. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol. 1998; 51:364-369. (Pubitemid 28289122)
8. Kawano-Yamamoto C, Muroi K, Izumi T, et al. Two-color flow cytometry with a CD19 gate for the evaluation of bone marrow involvement of B-cell lymphoma. Leuk Lymphoma. 2002;43: 2133-2137. (Pubitemid 35174725)
9. Torlakovic E, Torlakovic G, Nguyen PL, et al. The value of antipax- 5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker. Am J Surg Pathol. 2002;26:1343-11135
10. Yang W, Agrawal N, Patel J, et al. Diminished expression of CD19 in B-cell lymphomas. Cytometry B Clin Cytom. 2005;63:28-35. (Pubitemid 40096842)
11. Tzankov A, Went P, Zimpfer A, et al. Tissue microarray technology: principles, pitfalls and perspectives-lessons learned from hematological malignancies. Exp Gerontol. 2005;40:737-744. (Pubitemid 41265824)
12. Zimpfer A, Schönberg S, Lugli A, et al. Construction and validation of a bone marrow tissue microarray. J Clin Pathol. 2007;60: 57-61. (Pubitemid 46142672)
13. Bernasconi B, Karamitopolou-Diamantis E, Tornillo L, et al. Chromosomal instability in gastric mucosa-associated lymphoid tissue lymphomas: a fluorescent in situ hybridization study using a tissue microarray approach. Hum Pathol. 2008;39:536-542.
14. Tzankov A, Meier C, Hirschmann P, et al. Correlation of high numbers of intratumoral FOXP3+ regulatory T-cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin lymphoma. Haematologica. 2008;93:193-200.
15. Ryan DH, Nuccie BL, Ritterman I, et al. Expression of interleukin-7 receptor by lineage-negative human bone marrow progenitors with enhanced lymphoid proliferative potential and B-lineage differentiation capacity. Blood. 1997;89:929-940. (Pubitemid 27121286)
16. Bonzheim I, Geissinger E, Roth S, et al. Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling. Blood. 2004;104: 3358-3360. (Pubitemid 39507158)
17. Bradbury LE, Kansas GS, Levy S, et al. The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J Immunol. 1992; 149:2841-2850.
18. Harada H, Kawano M, Huang N, et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood. 1993;81:2658-2663. (Pubitemid 23147570)
19. Nadler LM, Anderson KC, Marti G, et al. B4, a human B lymphocyte-associated antigen expressed on normal, mitogenactivated, and malignant B lymphocytes. J Immunol. 1983;131:244-250.
20. Poe J, Hasegawa M, Tedder T. CD19, CD21, and CD22: multifaceted response regulators of B lymphocyte signal transduction. Int Rev Immunol. 2001;20:739-762.
21. Schriever F, Freedman A, Freeman G, et al. Isolated human follicular dendritic cells display a unique antigenic phenotype. J Exp Med. 1989;169:2043-2058. (Pubitemid 19162965)
22. Tedder T, Zhou L, Engel P. The CD19/CD21 signal transduction complex of B lymphocytes. Immunol Today. 1994;15:437-442. (Pubitemid 24272189)
23. Uckun F, Jaszcz W, Ambrus J, et al. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood. 1988;71:13-29. (Pubitemid 18050385)
24. Masir N, Marafioti T, Jones M, et al. Loss of CD19 expression in Bcell neoplasms. Histopathology. 2006;48:239-246.
25. Delsol G, Meggetto F, Brousset P, et al. Relation of follicular dendritic reticulum cells to Reed-Sternberg cells of Hodgkin's disease with emphasis on the expression of CD21 antigen. Am J Pathol. 1993;142:1729-1738. (Pubitemid 24057067)
26. Watanabe K, Yamashita Y, Nakayama A, et al. Varied B-cell immunophenotypes of Hodgkin/Reed-Sternberg cells in classic Hodgkin's disease. Histopathology. 2000;36:353-361. (Pubitemid 30198918)
27. Tiacci E, Pileri S, Orleth A, et al. PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia. Cancer Res. 2004;64:7399-7404. (Pubitemid 39372080)
28. Valbuena J, Medeiros L, Rassidakis G, et al. Expression of B cellspecific activator protein/PAX5 in acute myeloid leukemia with t(8;21)(q22;q22). Am J Clin Pathol. 2006;126:235-240. (Pubitemid 44162570)
29. Toth B, Wehrmann M, Kaiserling E, et al. Immunophenotyping of acute lymphoblastic leukaemia in routinely processed bone marrow biopsy specimens. J Clin Pathol. 1999;52:688-692. (Pubitemid 29456907)
30. Lai R, Juco J, Lee S, et al. Flow cytometric detection of CD79a expression in T-cell acute lymphoblastic leukemias. Am J Clin Pathol. 2000;113:823-830. (Pubitemid 33051518)
31. Pilozzi E, Pulford K, Jones M, et al. Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma. J Pathol. 1998;186: 140-143. (Pubitemid 28467822)
32. Hertel CB, Zhou XG, Hamilton-Dutoit SJ, et al. Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin/Reed-Sternberg cells of classical Hodgkin lymphoma. Oncogene. 2002;21:4908-4920.
33. Paulsson K, Cazier J, Macdougall F, et al. Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: unexpected similarities with pediatric disease. Proc Natl Acad Sci USA. 2008;105:6708-6713. (Pubitemid 351754571)
34. Mullighan C, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007; 446:758-764. (Pubitemid 46582031)
35. Bousquet M, Broccardo C, Quelen C, et al. A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5. Blood. 2007;109: 3417-3423. (Pubitemid 46572531)